{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:07Z","timestamp":1791593827953,"version":"4.3.4"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Inhibition of terminal complement component 5 has proven effective in acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG) but requires intravenous or daily subcutaneous administration and is associated with an increased meningococcal infection risk. Targeting the complement alternative pathway (AP) may offer similar benefits while sparing the classical and lectin pathways, preserving some immune responses against infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of vemircopan, an oral, selective factor D inhibitor that blocks AP-mediated complement activation and amplification, in adults with AChR-Ab+ gMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This double-blind, parallel-group, placebo-controlled phase 2 randomized clinical trial was conducted between April 14, 2022, and April 3, 2024, at 60 sites across 8 countries. Adults with AChR-Ab+ gMG, Myasthenia Gravis\u2013Activities of Daily Living (MG-ADL) score of 5 or greater, and Myasthenia Gravis Foundation of America classes II through IV classification were eligible for inclusion. Data were unblinded in June 2024; final analysis was completed October 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Randomization 2:1:2 to twice-daily oral vemircopan, 180 mg or 120 mg, or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was the proportion of participants achieving a 2-point or greater reduction in MG-ADL total score from baseline for 4 consecutive weeks, without rescue therapy, during the 8-week, double-blind primary evaluation period. Secondary end points were change from baseline to week 8 in MG-ADL total score, Quantitative Myasthenia Gravis total score, and Neurological Disorders Fatigue questionnaire score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 99 individuals screened, 70 met eligibility criteria, and 29 were excluded. Of 70 participants randomized (vemircopan, 180 mg: n\u2009=\u200928; vemircopan, 120 mg: n\u2009=\u200914; placebo: n\u2009=\u200928), 38 participants (54%) were female; mean (SD) age at diagnosis was 45.4 (18.5) years. The proportion of participants achieving the primary end point did not differ significantly between placebo (18 of 28 [64%]; 90% CI, 47%-79%) and either vemircopan group (180 mg: 16 of 28 [57%]; 90% CI, 40%-73%; 120 mg: 8 of 14 [57%]; 90% CI, 33%-79%). No significant differences were observed for the secondary end points. No cases of meningococcal infection were reported; 1 participant died due to hepatic failure and 1 discontinued study treatment due to herpes simplex meningitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this double-blind, parallel-group, placebo-controlled phase 2 randomized clinical trial, vemircopan did not meet the prespecified threshold for efficacy, and consequently, the study was terminated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05218096?cond=NCT05218096&amp;amp;amp;viewType=Card&amp;amp;amp;rank=1\">NCT05218096<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.0902","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:30:45Z","timestamp":1777303845000},"page":"544","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Vemircopan in Generalized Myasthenia Gravis"],"prefix":"10.1001","volume":"83","author":[{"given":"Francesco","family":"Sacc\u00e0","sequence":"first","affiliation":[{"name":"GENESIS Department, Federico II University of Naples, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Gialdini","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan H.","family":"Vu","sequence":"additional","affiliation":[{"name":"University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[{"name":"Neurology Clinic, University Clinical Centre of Serbia, Belgrade, Serbia"},{"name":"Faculty of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Sgarzi","sequence":"additional","affiliation":[{"name":"Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Shaibani","sequence":"additional","affiliation":[{"name":"Nerve and Muscle Center of Texas, Houston"},{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bril","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiann-Horng","family":"Yeh","sequence":"additional","affiliation":[{"name":"Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan"},{"name":"Fu Jen Catholic University, New Taipei City, Taiwan"},{"name":"Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Reyes-Garrido","sequence":"additional","affiliation":[{"name":"Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Liao","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Metais","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J. P.","family":"van der Valk","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ALXN2050-MG-201 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Peltier","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Golsari","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Bang","family":"Liu","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra","family":"Khatri","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chang","family":"Huang","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Schneider-Gold","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clark","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Martinez","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Maria","family":"Mart\u00ednez Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian Then","family":"Bergh","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Rodriguez de Rivera","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Li","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Djordjevic","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Kushlaf","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eustasio","family":"Meca Lallana","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaraswamy","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Feinberg","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nicolle","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Maestri Tassoni","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsung","family":"Kang","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratna","family":"Bhavaraju-Sanka","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Mantegazza","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Khella","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Saba","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Morino","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ragole","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Desai","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowaree","family":"Leavell","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabeen","family":"Mahuwala","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaeem","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"for the ALXN2050-MG-201 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi260022r1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction.","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"noi260022r2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","article-title":"Myasthenia gravis-pathophysiology, diagnosis, and treatment.","volume":"200","author":"Tannemaat","year":"2024","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"noi260022r3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF02337460","article-title":"Anti AChR antibody: relevance to diagnosis and clinical aspects of myasthenia gravis.","volume":"9","author":"Mantegazza","year":"1988","journal-title":"Ital J Neurol Sci"},{"issue":"5","key":"noi260022r4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/jnnp.56.5.496","article-title":"Clinical implementation of anti-acetylcholine receptor antibodies.","volume":"56","author":"Somnier","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"noi260022r5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays.","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"noi260022r6","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future.","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"issue":"5","key":"noi260022r7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16229","article-title":"Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment.","volume":"31","author":"Gilhus","year":"2024","journal-title":"Eur J Neurol"},{"issue":"3","key":"noi260022r8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update.","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"noi260022r13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.molimm.2023.12.004","article-title":"Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration.","volume":"165","author":"Jindal","year":"2024","journal-title":"Mol Immunol"},{"key":"noi260022r14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537974","article-title":"Factor B as a therapeutic target for the treatment of complement-mediated diseases.","volume":"16","author":"Kavanagh","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"noi260022r15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.","volume":"30","author":"Stascheit","year":"2023","journal-title":"Eur J Neurol"},{"issue":"3","key":"noi260022r16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"noi260022r18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions.","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"issue":"2","key":"noi260022r19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207937","article-title":"Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 Vivacity-MG study.","volume":"102","author":"Antozzi","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"noi260022r20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi260022r21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/mus.26469","article-title":"The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: a meta-analysis.","volume":"59","author":"Frisaldi","year":"2019","journal-title":"Muscle Nerve"},{"issue":"2","key":"noi260022r22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"},{"issue":"6","key":"noi260022r23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/pmt-2018-0054","article-title":"Placebo responders and nonresponders: what\u2019s new?","volume":"8","author":"Frisaldi","year":"2018","journal-title":"Pain Manag"},{"issue":"5","key":"noi260022r24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi260022r25","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis.","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"issue":"2","key":"noi260022r26","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients.","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"issue":"20","key":"noi260022r28","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.2021011388","article-title":"Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.","volume":"138","author":"Kulasekararaj","year":"2021","journal-title":"Blood"},{"issue":"2","key":"noi260022r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2025.152876","article-title":"Inhibiting the alternative pathway of complement by reducing systemic complement factor B: randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen.","volume":"230","author":"McCaleb","year":"2025","journal-title":"Immunobiology"},{"issue":"10","key":"noi260022r30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies.","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"issue":"6","key":"noi260022r31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy.","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"noi260022r32","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3324\/haematol.2020.261826","article-title":"Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.","volume":"106","author":"Risitano","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"noi260022r33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"issue":"11","key":"noi260022r35","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","article-title":"Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria.","volume":"373","author":"Kelly","year":"2015","journal-title":"N Engl J Med"},{"key":"noi260022r27","year":"2024"},{"key":"noi260022r34","author":"Hoechsmann","year":"2024"},{"key":"noi260022r9","unstructured":"Soliris (eculizumab). Prescribing information. Alexion Pharmaceuticals; 2025. Accessed April 2, 2026. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/soliris_uspi.pdf"},{"key":"noi260022r10","unstructured":"Ultomiris (ravulizumab-cwvz). Prescribing information. Alexion Pharmaceuticals; 2025. Accessed April 2, 2026. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2025\/english\/ultomiris_uspi.pdf?rev=7ab9a5262ccb4e56a42a560d3107082d"},{"key":"noi260022r11","unstructured":"Zilbrysq (zilucoplan). Prescribing information. UCB; 2025. Accessed April 2, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf"},{"key":"noi260022r12","unstructured":"Bowden? M. Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalised myasthenia gravis in PREVAIL phase III trial. AstraZeneca. Accessed July 25, 2025. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/gefurulimab-nanobody-met-phase-iii-endpoints.html"},{"key":"noi260022r17","unstructured":"VOYDEYA (danicopan). Prescribing information. Alexion Pharmaceuticals; 2024. Accessed April 2, 2026. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/voydeya_uspi.pdf"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2848079\/jamaneurology_sacc_2026_oi_260022_1781297048.64478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:00:28Z","timestamp":1781535628000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2848079"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.0902","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}